A phase 1/phase 2 study to investigate safety, tolerability and efficacy with TG01/QS-21 vaccine administration in patients with confirmed KRAS or NRAS codon 12/13 mutation and high-risk smoldering multiple myeloma or multiple myeloma and evidence of measurable disease ≥ 1 line of treatment.

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502275-39-00

Acronym

OMC04

Enrollment

Registered

2022-12-21

Start date

2023-05-19

Completion date

Unknown

Last updated

2024-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Norway

None listed

Source: EU CTIS · Data processed: Feb 4, 2026